Please login to the form below

Not currently logged in
Email:
Password:

access

This page shows the latest access news and features for those working in and with pharma, biotech and healthcare.

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

Will also access Merck’s big-selling Neurobion and the Nasivin nasal decongestant range. ... The 3.4bn ($4.2bn) price tag agreed for the unit is at the lower end of analyst expectations and gives P&G access to big-selling brands such as Neurobion,

Latest news

  • GSK hands rare disease assets over to Orchard GSK hands rare disease assets over to Orchard

    Orchard are committed to patient access, and we’re confident that this agreement combined with the ongoing relationship between the two companies will support the progression of these valuable programmes to

  • Segmentation, evolved Segmentation, evolved

    a cluster of adaptations - from early market access involvement to re-engineered metrics - that I’ve observed in the evolution of various innovation-based life science business models. ... Research by Amgen, which has a PCSK9 called Repatha, suggests

  • NHS seeks 'solution creators' from within pharma NHS seeks 'solution creators' from within pharma

    Addressing IQVIA’s UK Market Access Summit he said: “Not withstanding the cold trade winds of Brexit, which I totally understand, I would content that we are moving into a new ... or patient access schemes.

  • EC grants MSD’s Prevymis orphan product designation EC grants MSD’s Prevymis orphan product designation

    to help ensure that appropriate patients have access to letermovir as soon as possible.”.

  • Pharma must do more on antibiotic resistance, Davos meeting hears Pharma must do more on antibiotic resistance, Davos meeting hears

    for AMR and bring them to market responsibly, ”citing the case of J&J’s new tuberculosis drug bedaquiline which is available in 100 countries with tight control of access. ... Also expected shortly is the publication of recommendations from the

More from news
Approximately 195 fully matching, plus 1,072 partially matching documents found.

Latest Intelligence

  • Brexit Means Brexit Brexit Means Brexit

    In addition, it wants an immigration system that allows pharma to attract talent from around the world as well as ‘predictable access’to funding and collaboration for scientific research. ... But it should also begin, privately at least, to stress

  • Beyond caring: learning from the unsung advocates in cancer care

    What can we do for advocates? Increasing patient access to advocates has the potential to fundamentally change the cancer experience for patients and their families. ... Increasing access to psychological therapies for advocates and families was also

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    Diagnosis of rare disease is challenging; physicians may only see a handful of cases in their career and information surrounding them is often lacking or difficult to access.

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    Diagnosis of rare disease is challenging; physicians may only see a handful of cases in their career and information surrounding them is often lacking or difficult to access.

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    But our approach and success also hinges on patients being able to access our medicines. ... But only 5% of patients in England can currently access these medicines routinely through the NHS.

More from intelligence
Approximately 64 fully matching, plus 370 partially matching documents found.

Latest appointments

  • Open Access Consulting appoints new director Open Access Consulting appoints new director

    Open Access Consulting appoints new director. Jayne Hurrell joins the group from Evidera. ... evidence. Commenting on the appointment, Dorinda Hickey, CEO of Open Access Consulting, said: “We are delighted to have Jayne on board.

  • Therachon poaches Shire’s Aled Williams Therachon poaches Shire’s Aled Williams

    Therachon poaches Shire’ s Aled Williams. He becomes the biotech’s chief commercial officer and head of patient access. ... Therachon, a clinical-stage biotechnology company, has appointed Aled Williams to the position of chief commercial officer and

  • Claes Buxfeldt joins NDA Claes Buxfeldt joins NDA

    He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

  • Open Health creates new role Open Health creates new role

    In order to strengthen their experience and expertise, healthcare communications and market access group Open Health has appointed Gavin Jones into its newly formed role of director of rare disease. ... Joining the agency with twenty

  • Acumen appoints new strategy director Acumen appoints new strategy director

    Bols has also worked in the areas of market access, government affairs, public affairs, health policy and corporate communications to name a few and he has also advised companies engaging with

More from appointments
Approximately 6 fully matching, plus 149 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 26 fully matching, plus 389 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics